Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Exciting developments have recently emerged in the field of RNA therapeutics, with potential applications in the treatment of human diseases. The second International Conference on RNA in drug development was held to highlight several novel RNA-based technologies, including different approaches to silence gene expression, the broad range of diagnostic and therapeutic applications for aptamers, and the targeting of RNA with small molecules. Highlights of the meeting included the utilisation of RNA interference to silence genes, with applications for the treatment of both cancer and viral infections, and for systemic silencing of gene expression. Novel approaches to safer drug design using aptamers were presented, which would enable control of their therapeutic activity to be achieved with antidote oligonucleotides. Updates were also presented on the clinical and preclinical development of ribozymes and aptamers, including good progress in increasing the half-life of these molecules in serum.

Original publication

DOI

10.1517/14728222.7.2.299

Type

Conference paper

Publication Date

04/2003

Volume

7

Pages

299 - 303

Keywords

Animals, Antineoplastic Agents, Antiviral Agents, Aptamers, Nucleotide, Biosensing Techniques, Clinical Trials, Phase II as Topic, Drug Design, Drug Evaluation, Preclinical, Genetic Vectors, HIV Infections, Hepatitis C, Chronic, Humans, Mice, Neoplasms, RNA, RNA Interference, RNA, Small Interfering, Tumor Necrosis Factor-alpha